Boosting the pipeline
If you’ve been keeping an eye on biotech, you know the personalized cancer vaccine from Merck and Moderna is a total game-changer. Merck CEO Rob Davis just spilled the tea to CNBC: they’re officially working to speed up the manufacturing process. Right now, it takes six weeks to sequence a patient’s tumor and create a vaccine tailored to their specific mutations. That’s a long time when you’re dealing with aggressive diseases, but Davis confirmed they have the tech under control and are aiming to cut that time down. It’s giving efficiency, and honestly, we love to see it.
Why it matters
This isn't just about the vaccine. Merck is currently prepping for a major financial pivot as the patent for their blockbuster drug, Keytruda, nears its expiration. With $65 billion poured into acquisitions and new R&D facilities like their massive new 120,000-square-foot 'Advance' center in Pennsylvania, the company is hustling to make sure their revenue stream stays protected. They’re also fighting a legal battle over their newer subcutaneous version of Keytruda, but with a solid pipeline of new meds like the rare lung disease treatment Winrevair, Merck is clearly playing the long game to stay a market leader. Real talk: the transition from a 'revenue cliff' to a manageable business hill is the ultimate test for their stock, so keep your eyes on how these new launches perform.
